Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C] raclopride

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 4, 2013, Pages 574-579

  Kodaka, Fumitoshi ^a,b   Ito, Hiroshi ^a   Kimura, Yasuyuki ^a   Fujie, Saori ^a   Takano, Harumasa ^a   Fujiwara, Hironobu ^a   Sasaki, Takeshi ^a   Nakayama, Kazuhiko ^b   Halldin, Christer ^c   Farde, Lars ^c   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

11C MNPA; 11C Raclopride; Dopamine D2 3 receptor; High affinity state; Test retest reproducibility

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; MNPA C 11; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN; CAUDATE NUCLEUS; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DRUG RECEPTOR BINDING; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; TEST RETEST RELIABILITY;

ADULT; APOMORPHINE; BRAIN; DATA INTERPRETATION, STATISTICAL; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REPRODUCIBILITY OF RESULTS;

EID: 84875745577     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2312-8     Document Type: Article

References (11)

1. De Lean A, Kilpatrick BF, Caron MG. Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists. Mol Pharmacol 1982;22:290-7.
2. Seeman P, Tallerico T, Ko F, Tenn C, Kapur S. Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 2002;46:235-9.
3. Seneca N, Finnema SJ, Farde L, Gulyás B, Wikström HV, Halldin C, et al. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride. Synapse 2006;59:260-9.
4. Gao YG, Baldessarini RJ, Kula NS, Neumeyer JL. Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. J Med Chem 1990;33:1800-5.
5. Seeman P, Wilson A, Gmeiner P, Kapur S. Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse 2006;60:205-11.
6. Skinbjerg M, Namkung Y, Halldin C, Innis RB, Sibley DR. Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors. Synapse 2009;63:462-75.
7. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 2010;68:392-9.
8. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153-8.
9. Fleiss J. The design and analysis of clinical experiments. New York: Wiley; 1986.
10. Hirvonen J, Aalto S, Lumme V, Någren K, Kajander J, Vilkman H, et al. Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride. Nucl Med Commun 2003;24:1207-14.
11. Otsuka T, Ito H, Halldin C, Takahashi H, Takano H, Arakawa R, et al. Quantitative PET analysis of the dopamine D2 receptor agonist radioligand 11C-(R)-2-CH3O-N-n-propylnorapomorphine in the human brain. J Nucl Med 2009;50:703-10.